Fox Chase Cancer Center Welcomes Dr. J. Ryan Mark

Dr mark
J. Ryan Mark, MD, FACS, has joined Fox Chase as an Associate Professor in the Department of Urology and the Fox Chase – Temple Urologic Institute.

PHILADELPHIA (July 2, 2024) — Fox Chase Cancer Center is pleased to announce the hiring of J. Ryan Mark, MD, FACS, as an Associate Professor in the Department of Urology and the Fox Chase – Temple Urologic Institute

Mark is joining Fox Chase from Thomas Jefferson University Hospital, where he served most recently as the Vice Chair of Clinical Research and the Clinical Director of the Sidney Kimmel Cancer Center Biorepository. From 2016 through 2022, he was the Director of the Department of Urology Clinical Trials. He was also an Assistant Professor of Urology at the Sidney Kimmel Medical College at Thomas Jefferson University. 

“We are thrilled to welcome Dr. Mark to our nationally ranked department of urology. His arrival strengthens our position as a rapidly expanding leader in the management of both urologic malignancies and advanced urologic diseases,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology. 

Mark earned his medical degree from the Saint Louis University School of Medicine. He then completed an internship and residency in general surgery, as well as a residency in urologic surgery, at Thomas Jefferson University Hospital. He then completed a fellowship in urologic oncology at the Carolinas HealthCare System’s Levine Cancer Institute. 

He has been instrumental in organizing numerous scientific meetings, delivered a multitude of invited lectures, authored seven book chapters, and has over 60 publications, abstracts, and presentations to his credit. He has also been the principal investigator or co-investigator on nearly 40 clinical trials in urologic oncology. 

“Dr. Mark brings exceptional experience and expertise in all modalities of urologic oncologic surgery, including advanced robotics, open surgical techniques, and advanced office procedures such as transperineal prostate biopsies,” Kutikov said. “His status as a key opinion leader in urologic oncology and his leadership in clinical trials and research will significantly enhance the Fox Chase - Temple Urologic Institute and further extend its reach.” 

Mark is a member of the American Urological Association, the American College of Surgeons, the Endourological Society, and the European Association of Urology, as well as the Philadelphia Urological Society and the Philadelphia County Medical Society. 

Mark began his tenure at Fox Chase on July 1.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427